Photo by Robina Weermeijer on Unsplash

Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa

• Post author:Jessica Lynn
• Post published:March 27, 2024
• Post category:Lung Cancer/Rare Disease

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: A Potential Treatment Turning Point for ALK-Positive NSCLC: Dr. Ken Culver Shares Insights from the Phase 3 ALINA Study on Alecensa

source: shutterstock.com

November is Lung Cancer Awareness Month

• Post author:James Moore
• Post published:November 3, 2023
• Post category:Lung Cancer/Small cell lung cancer

The month of November is recognized around the world as Lung Cancer Awareness Month, a time to advocate and spread awareness about lung cancer. This form of cancer is not…

Continue Reading November is Lung Cancer Awareness Month

(2010). "Imaging lung manifestations of HIV/AIDS". Annals of Thoracic Medicine 5 (4): 201. DOI:10.4103/1817-1737.69106. ISSN 1817-1737. Creative Commons Attribution License

When Lung Cancer Occurs in Non-Smokers: An Exploration

• Post author:Jessica Lynn
• Post published:October 11, 2023
• Post category:Lung Cancer

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading When Lung Cancer Occurs in Non-Smokers: An Exploration

source: pixabay.com

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

• Post author:Rose Duesterwald
• Post published:October 2, 2023
• Post category:Lung Cancer

Over 50% of non-small cell lung cancer patients (NSCLC) will experience a recurrence after surgery. The cancer recurs even after adjuvant chemotherapy after major surgery. ALINA’s data show that Alecensa…

Continue Reading ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

source: shutterstock.com

Non-small Cell Lung Cancer: Alecensa Achieved Disease-Free Survival in Phase III Interim Analysis

• Post author:Rose Duesterwald
• Post published:September 28, 2023
• Post category:Lung Cancer/non-small cell lung cancer

   Currently, almost half the patients with non-small cell lung cancer (NSCLC) will see their disease return despite aggressive chemotherapy treatment (adjuvant surgery). Adjuvant therapy is treatment that is given…

Continue Reading Non-small Cell Lung Cancer: Alecensa Achieved Disease-Free Survival in Phase III Interim Analysis

source: pixabay.com

28-Year-Old Alix Lived a Full Life in the Face ALK Positive Lung Cancer

• Post author:Rose Duesterwald
• Post published:March 8, 2023
• Post category:Lung Cancer

   In March of 2021, twenty-eight-year-old Alix Burnard of Newbury, Berkshire UK had several Covid-19 tests due to a suspected infection. All three tests were negative, so she felt it…

Continue Reading 28-Year-Old Alix Lived a Full Life in the Face ALK Positive Lung Cancer

The FDA Approves New Combination Treatment for Non-Small Cell Lung Cancer

• Post author:Rose Duesterwald
• Post published:December 12, 2022
• Post category:Lung Cancer

The CDC lists lung cancer as the third most common type of cancer in the United States with the highest death rate. Estimates are given of 2.2 million patients worldwide…

Continue Reading The FDA Approves New Combination Treatment for Non-Small Cell Lung Cancer